Ivermectin in Cancer Research: Mechanisms, Dosage Protocols, and Musculoskeletal Implications

In the era of integrative oncology, a very old antiparasitic drug has been rediscovered as ivermectin. Its original purpose was for use as an antiparasitic drug, and now it is being investigated in preclinical and early phase clinical trials of cancer, and has been suggested to affect the tumor microenvironment, enhance the immune response, and be used in combination with other metabolic and repurposed drugs.

Ivermectin and Cellular Mechanisms

We previously demonstrated that ivermectin shows various anticancer activities at the cellular level by targeting PAK1 signaling, Akt/mTOR, WNT-TCF pathways and thereby affecting the stem-like properties of cancer cells. These shared signaling networks are associated with proliferation, angiogenesis and drug resistance, which implies that ivermectin will only be effective when combined with conventional cancer therapies, and thus functioning as a synergistic adjuvant therapeutic agent. Here we report the initiation of the first-in-human trial, NCT05318469: “Ivermectin Adjuvant Immunotherapy (IMM-101) for Patients with Advanced Solid Cancers”. A detailed analysis of this trial is available in the Sanare Lab review of ivermectin and immunotherapy.

Relevance to Muscle and Connective Tissue

Cancer cachexia or skeletal muscle wasting is a serious side effect of many types of cancer. This review is a primer on how researchers have come to study the condition and how understanding the pathways of muscle wasting in cachexia may give clues to the general effects of cancer on the musculoskeletal system. Many of the drugs used in cancer therapy also result in wasting of skeletal muscle, an effect that could be blocked by drugs such as ivermectin that inhibit the Akt/mTOR signaling pathway that promotes muscle protein synthesis.

Ivermectin Dosage and Safety in Cancer Protocols

Ivermectin is not an FDA-approved cancer medication, therefore there is not a standard oncology dose and its use in cancer therapy would be considered off-label, and any such use would need careful consideration of benefit vs risk, including potential drug interactions. Sanare Lab has synthesized the current knowledge related to safe and effective dosing of ivermectin in cancer based upon the pharmacology and a titration scheme grounded in rigorous scientific principles and practices for the reduction of adverse effects, including need for liver function testing and contraindications screen. The full ivermectin dosage and safety guide for cancer protocols is available here.

Looking Ahead

This may change as future research and studies with larger numbers of participants and longer follow-up are published and more information becomes available. Ivermectin, like artemisinin, may simply be a footnote in the story of fighting cancer and other diseases and treating muscle wasting. The use of repurposed drugs as part of effective, evidence-based treatments is a developing and evolving field of translational science that merges pharmacology, oncology and muscle biology.

This article is for educational and informational purposes only and does not constitute medical advice.

Written by codingwithmucchi@gmail.com